Comparison of the efficacy and pharmacology of formulations of amphotericin B used in treatment of leishmaniasis

Current Opinion in Infectious Diseases

Volumn 18, Issue 6, 2005, Pages 527-530

  Barratt, Gillian ^a,c   Legrand, Philippe ^b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIV MONTPELLIER   (France)

^c UNIV PARIS SUD   (France)

Author keywords

Amphotericin B; HIV; Leishmaniasis; Lipid formulation; Resistance

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; GRANULOCYTE COLONY STIMULATING FACTOR; LIPOSOME; MICROSPHERE; MILTEFOSINE; SAPONIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CONGENITAL HYPOTHYROIDISM; COST OF ILLNESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TOLERANCE; ENDEMIC DISEASE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; IMMUNOMODULATION; LEISHMANIA DONOVANI; LEISHMANIASIS; LUNG TUBERCULOSIS; NONHUMAN; PREGNANCY; REVIEW; T LYMPHOCYTE; VISCERAL LEISHMANIASIS;

EID: 27744505924     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000191508.48481.f4     Document Type: Review

References (45)

1. Gaeta GB. Clinical signs of visceral leishmaniasis in adults: is the manner of presentation changing? [in Italian] Parassitologia 2004; 46:225-226.
2. Singh S, Sivakumar R. Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother 2004; 10:307-315. A fairly short but exhaustive review.
3. Murray HW. Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis. J Immunol 2005; 174:4916-4923. An interesting study using mouse strains with different genetic backgrounds to determine the role of immune mechanisms in clearing infection.
4. Vonk AG, Netea MG, Denecker NE, et al. Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B. J Antimicrob Chemother 1998; 42:469-474.
5. Thakur CP, Narayan S, Ranjan A. Epidemiological, clinical and pharmacological study of antimony-resistant visceral leishmaniasis in Binar, India. Indian J Med Res 2004; 120:166-172. This study concludes that amphotericin B should replace sodium antimony gluconate as a first-line treatment.
6. Thakur CP, Narayan S. A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol 2004; 98:129-138.
7. Aguado JM, Lumbreras C, Gonzalez-Vidal D, Grupo de Farmacovigilancia de Abelcet. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain. Clin Microbiol Infect 2004; 10:785-790.
8. Sundar S, Mehta H, Suresh AV, et al. Amphotericin B treatment for Indian visceral leishmaniasis; conventional versus lipid formulations. Clin Infect Dis 2004; 38:377-383. Open label study comparing lipid formulations of amphotericin B with the deoxycholate formulation.
9. Gradoni L, Gramiccia M, Scalone A. Change in human visceral leishmaniasis treatment in Italy: retrospective study of 630 patients. [in Italian] Parassitologia 2004; 46:199-201.
10. Goldsmith DR, Perry CM. Amphotericin B lipid complex: in visceral leishmaniasis. Drugs 2004; 64:1905-1911; discussion 1912-1913.
11. Murray HW. Treatment of visceral leishmaniasis in 2004. Am J Trop Med Hyg 2004; 71:787-794; erratum 2005; 72:359. A review which puts new developments in the treatment of kala-azar into perspective.
12. Murray HW. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert Rev Anti Infect Ther 2004; 2:279-292; erratum 462.
13. Berman J. Recent developments in leishmaniasis: epidemiology, diagnosis, and treatment. Curr Infect Dis Rep 2005; 7:33-38.
14. Dupouy-Camet J. [New drugs for the treatment of human parasitic protozoa.] Parassitologia 2004; 46:81-84.
15. Paradisi A, Capizzi R, Zampetti A, et al. Atypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin B. J Infect 2005; 1 June [Epub ahead of print].
16. Markle WH, Makhoul K. Cutaneous leishmaniasis: recognition and treatment. Am Fam Physician 2004; 69:1455-1460.
17. Virgilio GR, Hale BR. A case of mucocutaneous leishmaniasis. Otolaryngol Head Neck Surg 2005; 132:800-801.
18. Ju O, Grove DI, Jaksic WJ, Dart GW. Visceral leishmaniasis: a trip to the Greek Islands is not always idyllic. Med J Aust 2004; 181:446-447.
19. Figueiro-Filho EA, Duarte G, El-Beitune P, et al. Visceral leishmaniasis (kalaazar) and pregnancy. Infect Dis Obstet Gynecol 2004; 12:31-40.
20. Pagliano P, Carannante N, Rossi M, et al. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J Antimicrob Chemother 2005; 55:229-233.
21. Queiroz MJ, Alves JG, Correia JB. Visceral leishmaniasis: clinical and epidemiological features of children in an endemic area. [in Portuguese] J Pediatr 28Rio J) 2004; 80:141-146.
22. Kafetzis DA, Velissariou IM, Stabouli S, et al. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds? Int J Antimicrob Agents 2005; 25:26-30. Study from Greece which includes an analysis of costs.
23. Cascio A, di Martino L, Occorsio P, et al. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience. J Antimicrob Chemother 2004; 54:217-220.
24. Minodier P, Robert S, Noel G, et al. First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France. [in French] Arch Pediatr 2005; 12:1102-1108.
25. Sinha PK, Pandey K, Bhattacharya SK. Diagnosis and management of leishmania/HIV co-infection. Indian J Med Res 2005; 121:407-414.
26. Calza L, D'Antuono A, Marinacci G, et al. Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS. J Am Acad Dermatol 2004; 5:461-465.
27. Pandey K, Sinha PK, Ravidas VN, et al. Nexus of infection with human immunodeficiency virus, pulmonary tuberculosis and visceral leishmaniasis: a case report from Bihar, India. Am J Trop Med Hyg 2005; 72:30-32.
28. Schraner C, Hasse B, Hasse U, et al. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clin Infect Dis 2005; 40:120-124.
29. Amato VS, Rabello A, Rotondo-Silva A, et al. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Trop 2004; 92:127-132.
30. Mastroianni A. Liposomal amphotericin B and rHuGMCSF for treatment of visceral leishmaniasis in AIDS. Infez Med 2004; 12:197-204.
31. Lopez-Velez R, Videla S, Marquez M, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004; 53:540-543. Multicentre trial with 115 patients showing that lipid-associated amphotericin B can prevent relapse, with minimal toxicity.
32. Montana M, Chochoi N, Monges P, et al. Liposomal amphotericin B in secondary prophylaxis of visceral leishmaniasis in HIV-infected patients: report of five clinical cases. [in French] Pathol Biol (Paris) 2004; 52:66-75.
33. Maggi P, Gaudiano V, Valente M, et al. Leishmaniasis in patients with chronic renal failure: a diagnostic and therapeutic challenge for the clinician. J Nephrol 2004; 17:296-301.
34. Sirvent-von Bueltzingsloewen A, Marty P, Rosenthal E, et al. Visceral leishmaniasis: a new opportunistic infection in hematopoietic stem-cell-transplanted patients. Bone Marrow Transplant 2004; 33:667-668.
35. Castellino G, Govoni M, Lo Monaco A, et al. Visceral leishmaniasis complicating a connective tissue disease: three case reports from Italy. Lupus 2004; 13:201-203.
36. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat 2004; 7:257-66. An interesting review which details resistance mechanisms.
37. Mbongo N, Loiseau P, Billion MA, et al. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob Agents Chemother 1998; 42:352-357.
38. Oliva G, Foglia Manzillo V, Pagano A. [Canine leishmaniasis: evolution of the chemotherapeutic protocols.] Parassitologia 2004; 46:231-234.
39. Dube A, Singh N, Sundar S, Singh N. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res 2005; 96:216-223. Drug sensitivity of clinical isolates.
40. Maes L, Germonprez N, Quirijnen L, et al. Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters. Antimicrob Agents Chemother 2004; 48:2056-2060. A report of an interesting new drug.
41. Dea-Ayuela MA, Rama-Iniguez S, Sanchez-Brunete JA, et al. Anti-leishmanial activity of a new formulation of amphotericin B. Trop Med Int Health 2004; 9:981-990.
42. Sanchez-Brunete JA, Dea MA, Rama S, et al. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother 2004; 48:3246-3252.
43. Sanchez-Brunete JA, Dea MA, Rama S, et al. Amphotericin B molecular organization as an essential factor to improve activity/toxicity ratio in the treatment of visceral leishmaniasis. J Drug Target 2004; 12:453-460.
44. Santarem N, Tomas A, Ouaissi A, et al. Antibodies against a Leishmania infantum peroxiredoxin as a possible marker for diagnosis of visceral leishmaniasis and for monitoring the efficacy of treatment. Immunol Lett 2005; 101:18-23.
45. Kayser O, Olbrich C, Yardley V, et al. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 2003; 254:73-75.